Cyprotex PLC Appointment of Leader of Drug Transporter Team
March 12 2015 - 3:01AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
12 March 2015
Cyprotex PLC
("Cyprotex" or "the Company")
Cyprotex appoints Dr Rob Elsby as Leader of Drug Transporter
Team.
Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research
Organisation (CRO), today announces the appointment of Dr Rob Elsby
as Leader of its Drug Transporter Team. Dr Elsby is a recognised
expert in the drug transporter field, as exemplified by his
numerous publications including co-authoring an International
Transporter Consortium (ITC) whitepaper. These publications span
such areas as the validation of in vitro transporter assays,
predicting clinical DDI exposure changes for statins, and the role
that transporter pharmacogenetics play in mediating ethnic
differences in statin exposure. Dr Elsby's role at Cyprotex will
involve leading the strategic direction of Cyprotex's transporter
based assays both in terms of new research and its client-based
services.
Prior to joining Cyprotex, Dr Elsby worked within a DMPK (Drug
Metabolism and Pharmacokinetics) function at AstraZeneca where,
over a period of 11 years, he helped develop the internal drug
transporter scientific capability both practically and
strategically. During this time his expert knowledge and technical
interpretation of drug transporter science was routinely used
towards the provision of drug disposition and clinical DDI
(drug-drug interaction) risk understanding to global discovery and
development project teams.
Dr Elsby will be presenting new research performed at Cyprotex
in the field of transporters at the AAPS/ITC Joint Workshop on Drug
Transporters in Baltimore, USA in April 2015. The research focuses
on the impact of inhibitor pre-incubation time on uptake
transporter interactions in vitro.
On joining Cyprotex, Dr Elsby said "I am very excited to be
joining a leading scientific team that can utilise its specialist
services/expertise to fully integrate in vitro ADME, transporter
and toxicity data with PBPK (physiologically based pharmacokinetic)
modelling approaches towards obtaining a more holistic prediction
of a molecule's safety profile in humans."
Dr Anthony Baxter, Cyprotex's Chief Executive Officer said, "We
are delighted to welcome Dr Elsby to our scientific team. Rob's
experience in the extrapolation of in vitro drug transporter
interactions to the clinical situation will be vital in assisting
our customers in understanding the relevance of the data generated.
Through expansion of its transporter capabilities, Cyprotex can now
offer the full range of in vitro assays for regulatory DDI
(drug-drug interaction) packages."
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1000 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. The Company's core capabilities include high quality in
vitro ADME screening services, mechanistic toxicology and high
content toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, predictive modelling
using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK
prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGUWWWUPAGQG
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024